- Trial Phase
- Phase 3 (discontinued in NSCLC); Phase 2/3 (AIPAC-003 in breast cancer); Phase 2b (TACTI-003 in HNSCC)
- Time to Market
- At least 3-5 years — no drug has been filed for approval. The most advanced program (TACTI-003 in HNSCC) has FDA support for late-stage development but has not yet started a registrational trial.
- Why 6/10
- The next hard catalyst is the TACTI-004 root cause analysis results, expected in Q3 CY2026 (within ~3 months). This analysis will determine whether the Phase III NSCLC failure was due to a specific, fixable issue or a fundamental efficacy problem — a binary that could either validate or further damage efti's development prospects. Since efti is essentially Immutep's only asset and the stock has already crashed ~85% from its highs, the outcome could drive a significant move, but it's a diagnostic report rather than a classic PDUFA/pivotal readout.
Watch for the TACTI-004 root cause analysis expected in Q3 2026 — a positive explanation (e.g., a specific trial-design issue) could partially revive the thesis, while a confirmation of broad efficacy failure would be another severe blow. The Dr. Reddy's partnership ($20M upfront, up to $349.5M in milestones) provides some non-dilutive funding and emerging-markets validation. The stock trades near cash value (~$99M market cap vs ~$99M cash), limiting downside but reflecting deep skepticism after the Phase III failure.
Price Chart
Executive Summary
Eftilagimod alfa (efti) is Immutep's only clinical-stage asset — a first-in-class LAG-3 agonist that activates the immune system against cancer. The drug suffered a major blow in March 2026 when the Phase III TACTI-004 trial in first-line NSCLC was discontinued for futility, causing an ~85% stock crash. However, the drug maintains promising pipelines in head and neck cancer (positive TACTI-003 Phase IIb with FDA backing for a path forward), metastatic breast cancer (ongoing AIPAC-003 Phase II/III), and soft tissue sarcoma (Phase II success, FDA Orphan Drug Designation). A root cause analysis of the NSCLC failure is due in Q3 2026 and will be a critical catalyst. The company has ~$99M in cash and a Dr. Reddy's partnership ($20M upfront) providing some financial runway.
How It Works
Eftilagimod alfa is a soluble LAG-3 protein that acts as an immune system stimulator — it binds to MHC Class II molecules on immune cells called antigen-presenting cells (dendritic cells, monocytes) and activates them, which in turn helps recruit and expand cancer-killing T cells. Unlike most LAG-3-targeted drugs which block the LAG-3 receptor (inhibitors), efti activates LAG-3 signaling (agonist) to boost both the innate and adaptive arms of the immune system.
Trial Status
The Phase III TACTI-004 trial in first-line NSCLC was discontinued in March 2026 after an interim futility analysis (ORR 42.9% efti arm vs 55.1% control). The Phase II/III AIPAC-003 trial in metastatic breast cancer completed its Phase II dose-optimization portion (selecting 30mg dose) and the Phase III portion is ongoing. The Phase IIb TACTI-003 trial in HNSCC reported positive topline results; FDA has supported continued late-stage development in PD-L1 CPS<1 patients. The Phase II EFTISARC-NEO trial in soft tissue sarcoma met its primary endpoint, leading to FDA Orphan Drug Designation in April 2026. A root cause analysis of the TACTI-004 failure is underway with results expected Q3 CY2026.
The Two-Sided Case
Upcoming Catalysts
- Q3 CY2026: TACTI-004 root cause analysis results — could explain why efti failed in NSCLC and determine the path forward for the program
- Regulatory path update for TACTI-003 in HNSCC (PD-L1 CPS<1 population) — FDA feedback supports late-stage development; specific registrational trial plans TBD
- AIPAC-003 Phase III enrollment completion and interim data readout in metastatic breast cancer (timeline undisclosed)
- Potential partnership or licensing deals for efti in North America or Europe (Dr. Reddy's covers only ex-North America/Europe/Japan/Greater China)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IMMUTEP Ltd 6-K IMMP ·Originating report